Bradner James E. 4

4 · AMGEN INC · Filed May 7, 2026

AI-generated summary of this filing

Updated May 8, 2026

AMGN EVP James Bradner Receives $7.18M Equity Award

What Happened

James E. Bradner, Executive Vice President, Research & Development at Amgen (AMGN), received equity awards on 2026-05-05: a derivative equity grant of 21,773 units valued at $329.59 each (~$7,176,163) and 3,337 restricted stock units (RSUs). On 2026-05-06, 407 shares were surrendered/disposed at $329.59 per share to satisfy tax withholding obligations (proceeds ≈ $134,143). The 407-share disposition is recorded as tax withholding (routine), not an open-market sale.

Key Details

Transaction dates and values:
- 2026-05-05: Award/grant — 21,773 derivative units @ $329.59 each = $7,176,163 (derivative award)
- 2026-05-05: Award/grant — 3,337 RSUs @ $0.00 (reported as grant)
- 2026-05-06: Tax withholding (F) — 407 shares disposed @ $329.59 = $134,143
Shares owned after transaction: Not specified in the filing.
Relevant footnotes from the filing:
- F1: RSUs vest in four equal annual installments (25% each) beginning 5/5/2027; vested RSUs paid 1:1 in common stock.
- F2: The award includes 1,332 Dividend Equivalents credited to unvested RSUs, paid in shares on vesting (plus cash for fractional shares).
- F3: The derivative units include non-qualified stock options that vest/exercise in four equal annual installments starting 5/5/2027.
Filing timeliness: Report filed 2026-05-07 for transactions on 2026-05-05/05-06 — appears to be a timely Form 4 filing.

Context

The large grants are typical long-term incentive awards (RSUs and stock options) that vest over multiple years; they are intended for retention and compensation rather than immediate market bets.
The 407-share disposition is a tax-withholding action (code F), a routine administrative step when equity awards are granted; it should not be interpreted as a discretionary sale of stock.
For options/derivative awards, note these grants vest beginning 5/5/2027 in four equal annual installments — the awards are not immediately exercisable.

Form 4

Period: 2026-05-05

EVP, Research and Development

Transactions

Award
Common Stock
[F1]
2026-05-05+3,337→ 30,869 total
Tax Payment
Common Stock
[F2]
2026-05-06$329.59/sh−407$134,143→ 30,462 total
Award
Nqso (Right to Buy)
[F3]
2026-05-05$329.59/sh+21,773$7,176,163→ 21,773 total
Exercise: $329.59From: 2027-05-05Exp: 2036-05-05→ Common Stock (21,773 underlying)

Footnotes (3)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F2]These shares include 1,332 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F3]These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.

Signature

/s/ Andrea A. Robinson, Attorney-in-Fact for Mr. Bradner|2026-05-07

1 file